Skip to main content
SpringerLink
Log in

IGF in the Treatment of Diabetes

  • Chapter
The IGF System

Part of the book series: Contemporary Endocrinology ((COE,volume 17))

Abstract

Since the identification of insulin-like growth factor-I (IGF-I) as one of the proteins responsible for the “nonsuppressible insulin-like activity” described by Froesch et al. (1),IGF-I has been an attractive candidate for use in the treatment of diabetes mellitus. IGF-I shares not only structural homology with insulin, but cognate receptor and post-receptor signaling similarities as well. The large-scale production of recombinant hIGF-I has led to an explosion in research characterizing the metabolic effects and therapeutic actions of IGF-I in different forms of diabetes. Initial studies focused on the use of IGF-I in patients with severe insulin resistance, a group in whom effective therapeutic options are quite limited. Early reports with this patient population provided the rationale for using IGF-I in both type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes. This chapter reviews the rationale for the use of exogenous IGF-I in different types of diabetes mellitus and summarizes the therapeutic trials that have been published based on treatment with IGF-I.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Froesch ER, Burgi H, Ramsier EB, Bally P, Labhart A. Antibody suppressible and nonsuppressible insulin-like activities in human sera and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963; 42: 1816–1834.

    Article  PubMed  CAS  Google Scholar 

  2. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317: 137–140.

    Article  PubMed  CAS  Google Scholar 

  3. Elahi D, McAloon-Dyke M, Fukagawa NK, Sclater AL, Wong GA, Shannon RP, Minaker KL, Miles JM, Rubenstein AH, Vanderpol CJ, Guler H-P, Good WR, Seaman JJ, Wolfe RA. Effects of recombinant human IGF-I on glucose and leucine kinetics in men. Am J Physiol 1993; 265: E831–838.

    PubMed  CAS  Google Scholar 

  4. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose—response relationships in healthy young and middle-aged adults. J Clin Invest 1994; 93: 1131–1139.

    Article  PubMed  CAS  Google Scholar 

  5. Dicola GD, Cook MH, Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 1997; 99: 2538–2544.

    Article  CAS  Google Scholar 

  6. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1994; 92: 2249–2256.

    Article  Google Scholar 

  7. Kerr D, Tamborlane WV, Rife F, Sherwin RS. Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin. J Clin Invest 1993; 91: 141–147.

    Article  PubMed  CAS  Google Scholar 

  8. Hussain MA, Schmitz O, Christiansen JS, Christensen NJ, Alberti KGMM, Froesch ER. IGF-I alters skeletal muscle substrate metabolism and blunts recovery from insulin-induced hypoglycemia. Am J Physiol 1996; 270: E1 - E7.

    Google Scholar 

  9. Dunger DB, Cheetham TD, Crowne EC. Insulin-like growth factors (IGFs) and IGF-1 treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 1995; 44 (Suppl 4): 119–123.

    Article  PubMed  CAS  Google Scholar 

  10. Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, Sherwin R. Insulin infusion pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303–307.

    Article  PubMed  CAS  Google Scholar 

  11. Clayton KL, Holly JM, Carlsson LM, Jones J, Cheetham TD, Taylor AM, Dunger DB. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 1994; 41: 517–524.

    Article  CAS  Google Scholar 

  12. Cotterill AM, Daly F, Holly JMP, Hughes SC, Camacho-Hubner C, Abdullah AF, Gale EAM, Savage MO. The `dawn phenomenon’ in adolescents with insulin-dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Clin Endocrinol 1995; 43: 567–574.

    Article  CAS  Google Scholar 

  13. Kobayashi K, Amemiya S, Sawabibiru E, Higashida K, Ishihara T, Kobayashi K, Kato K, Nakazawa S. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care 1997; 20: 1442–1447.

    Article  PubMed  CAS  Google Scholar 

  14. Quattrin T, Thrailkill KM, Baker L, Quarmby V, Compton P, Pappenheimer M, Martha PM. Low plasma free IGF-I levels in IDDM: additional evidence for a bihormonal defect in diabetes. Diabetes 1996; 45 (Suppl 2): 17A.

    Google Scholar 

  15. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA. Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995; 80: 1312–1317.

    Article  PubMed  CAS  Google Scholar 

  16. Shishko PI, Dreval AV, Abugova IA, Zajamy IU, Goncharov VC. Insulin-like growth factors and binding proteins in patients with recent onset type I diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 1995; 25: 1–12.

    Article  Google Scholar 

  17. Hanaire-Boutin H, Sallari-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, Tauber JP. Insulin therapy and GH-IGF-1 axis disorders in diabetes: impact of glycemic control and hepatic insulinization. Diab Metab 1996; 22: 245–250.

    Google Scholar 

  18. Tan K, Baxter RC. Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986; 63: 651–655.

    Article  PubMed  CAS  Google Scholar 

  19. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycemia in patients with extreme insulin resistance. Diabetologia 1991; 34: 675–691.

    Article  PubMed  CAS  Google Scholar 

  20. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall’ s syndrome. N Engl J Med 1990; 323: 1425 1426.

    Google Scholar 

  21. Morrow LA, O’Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205–210.

    Article  PubMed  CAS  Google Scholar 

  22. Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesen WF, Schoenle EJ, Froesch ER. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994; 131: 251–257.

    Article  PubMed  CAS  Google Scholar 

  23. Vestergaard H, Rossen M, Urhammer SA, Muller J, Pedersen O. Short-and long-term metabolic effects of recombinant human IGF-1 treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol 1997; 136: 475–482.

    Article  PubMed  CAS  Google Scholar 

  24. Kajimoto Kajimoto Y, Kawamori R, Fujitani Y, Kishimoto M, Kubota M, Yamasaki Y, Morishima T, Kamada T. A case of non-insulin dependent diabetes mellitus with antiinsulin antibody: effect of subcutaneous injection of human recombinant insulin-like growth factor-I. Endocr J 1995; 42: 101–105.

    Article  Google Scholar 

  25. Nakashima N, Umeda F, Yanase T, Nawata H. Insulin resistance associated with substitution of histidine for arginine 252 in the alpha-subunit of the human insulin receptor: trial of insulin-like growth factor I injection therapy to enhance insulin sensitivity. J Clin Endocrinol Metab 1995; 80: 3662–3667.

    Article  PubMed  CAS  Google Scholar 

  26. Ishihama H, Suzuki Y, Muramatsu K, Nagai M, Kokubo M, Shiraya H, Kawakita A, Nishimura Y, Imamura T, Koboyashi M. Long-term follow-up in type A insulin resistant syndrome treated by insulin-like growth factor-I. Arch Dis Child 1994; 71: 144–146.

    Article  PubMed  CAS  Google Scholar 

  27. Hernandez ER, Resnick CE, Svoboda ME, Van Wyck JJ, Payne DW, Adashi EY. Somatomedin C/insulin-like growth factor-1 as an enhancer of androgen biosynthesis by cultured rat ovarian cell. Endocrinology 1988; 122: 1603–1612.

    Article  PubMed  CAS  Google Scholar 

  28. Dozio N, Scavini M, Beretta A, Sartori S, Meschi F, Sarugeri E, Pozza G. In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor. J Clin Endocrinol Metab 1995; 80: 1325–1328.

    Article  PubMed  CAS  Google Scholar 

  29. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, Yoshimasi Y, Kasuga M, Goji K, Nagataki S, Oyasu H, Imura H. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696–705.

    Article  PubMed  CAS  Google Scholar 

  30. Moses AC, Morrow LA, O’Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28 (Suppl): S185–194.

    Article  PubMed  CAS  Google Scholar 

  31. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473–486.

    PubMed  CAS  Google Scholar 

  32. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234–2241.

    Article  PubMed  CAS  Google Scholar 

  33. Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563–1568.

    Article  PubMed  CAS  Google Scholar 

  34. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369–374.

    Article  PubMed  CAS  Google Scholar 

  35. Moses AC, Young SCJ, Morrow LA, O’Brien M, Clemmons DR. Recombinant human insulin-like growth factor-1 increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91–100.

    Article  PubMed  CAS  Google Scholar 

  36. RHIGF-1 in NIDDM Study Group. Evidence from a dose-ranging study that recombinant insulin-like growth factor-1 (RhIGF-1) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus. Diabetes 1996; 45 (Suppl 2): 27A

    Google Scholar 

  37. RHIGF-1 in NIDDM Study Group. Safety profile of rhIGF-1 therapy in patients with NIDDM: a dose ranging, placebo control trial. Diabetes 1996; 45 (Suppl 2): 71A

    Google Scholar 

  38. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor 1 binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988; 81: 976–981.

    Article  PubMed  CAS  Google Scholar 

  39. Ciaraldi TP, Abrams-Carter L, Park KS, Mudaliar S, Henry RR. IGF-1 compensates for impaired insulin action in skeletal muscle of NIDDM. Diabetes 1997; 46 (Suppl 1): 352A.

    Google Scholar 

  40. Zenobi PD, Holzman P, Glatz Y, Riesen WF, Froesch ER. Improvement of lipid profile in type 2 (non-insulin dependent) diabetes by insulin-like growth factor I. Diabetologia 1993; 16: 465–469.

    Article  Google Scholar 

  41. Moses A, Philips L, Martha P, Compton P, Zysow B for the RINDS and RICS Groups. RhIGF-1 improves coronary risk factors in type II diabetes (abstract). Diabetologia 1997; 40 (Suppl 1): 1484.

    Google Scholar 

  42. Padayatty SJ, Orme S, Zenobi PD, Strickland MH, Belchetz PE, Grant PJ. The effects of insulin-like growth factor 1 on plasminogen activator inhibitor-1 synthesis and secretion: results from in vitro and in vivo studies. Thromb Heaemost 1993; 70: 1009–1013.

    CAS  Google Scholar 

  43. Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP. Nutritional regulation of insulin-like growth factor-1. Metabolism 1995; 44 (Suppl 1): 50–57.

    Article  PubMed  CAS  Google Scholar 

  44. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor binding protein-1 modulates blood glucose levels. Endocrinology 1991; 129: 2254–2256.

    Article  PubMed  CAS  Google Scholar 

  45. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-1 infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1040–1045.

    Article  PubMed  CAS  Google Scholar 

  46. Cheetham TD, Clayton KL, Taylor AM, Holly J, Matyhews DR, Dungar DB. The effects of recombinant insulin-like growth factor-1 on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994; 40: 515–522.

    Article  CAS  Google Scholar 

  47. Cheetham TD, Holly JM, Clayton K, Cwyfan-Hughes S, Dungar DB. The effects of repeated daily recombinant human insulin-like growth factor 1 administration in adolescents with type 1 diabetes. Diabetic Med 1995; 12: 885–892.

    Article  PubMed  CAS  Google Scholar 

  48. Quattrin T, Thrailkill K, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Giltinan D, Gesundheit N, Martha P. Dual hormonal replacement with insulin and insulin-like growth factor 1 in IDDM. Effects on glycemic control, IGF-1 levels and safety profile. Diabetes Care 1997; 20: 374–380.

    Article  PubMed  CAS  Google Scholar 

  49. Thrailkill K, Quattrin T, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Kotlovker D, Giltinan D, Gesundheit N, Martha P. Dual hormonal replacement therapy with insulin and insulin-like growth factor 1 in insulin-dependent diabetes mellitus. Effects on the growth hormone/IGF/IGF-binding protein system. J Clin Endocrinol Metab 1997; 82: 1181–1187.

    Google Scholar 

  50. Thrailkill K, Quattrin T, Baker L, Kuntze J, Bajamonde A, Martha P, for the rhIGF-1 in IDDM Study Group. Co-therapy with recombinant human insulin-like growth factor-1 and insulin improves glycemic control in IDDM. Diabetes 1997; 46 (Suppl 1): 43A.

    Google Scholar 

  51. Acerini CL, Patton CM, Kernell A, Savvage MO, Westphal O, Dungar DB. A trial of insulin-like growth factor-1 as adjunct to multiple injection therapy in insulin dependent diabetes. Diabetologia 1997; 40 (Suppl 1): 1299.

    Google Scholar 

  52. Carroll PV, Umplegy AM, Ward GS, Imuere S, Alexander E, Dungar D, Sonksen PH, Russel-Jones DL. RhIGF-1 reduces growth hormone secretion, lipid levels, and insulin requirement in adults with IDDM. Diabetologia 1997; 40 (Suppl 1): 1487.

    Google Scholar 

  53. Crowne EC, Samra JS, Cheetham T, Watts A, Holly JMP, Dunger DB. Low dose recombinant human IGF-1 abolishes changes in insulin sensitivity consequent upon GH pulsatility in young adults with type 1 diabetes mellitus. Metabolism, in press.

    Google Scholar 

  54. Kopple JD, Ding H, Hirschberg R. Effects of recombinant human insulin-like growth factor-1 on renal handling of phosphorus, calcium, and sodium in normal humans. Am J Kidney Dis 1995; 26: 818–824.

    Article  PubMed  CAS  Google Scholar 

  55. Smith Le, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706–1709.

    Google Scholar 

Download references

Authors
  1. Robert A. Gabbay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan C. Moses MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, OR, USA

    Ron G. Rosenfeld MD

  2. Oregon Health Sciences University, Portland, OR, USA

    Charles T. Roberts Jr. PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gabbay, R.A., Moses, A.C. (1999). IGF in the Treatment of Diabetes. In: Rosenfeld, R.G., Roberts, C.T. (eds) The IGF System. Contemporary Endocrinology, vol 17. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-712-3_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-712-3_30

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-138-7

  • Online ISBN: 978-1-59259-712-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation